Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

160.39
+1.701.07%
Post-market: 160.390.00000.00%16:20 EDT
Volume:225.47K
Turnover:36.07M
Market Cap:9.13B
PE:31.73
High:161.04
Open:159.37
Low:158.33
Close:158.69
Loading ...

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

PR Newswire
·
18 Mar

Crane Company (CR): Among the Best Reddit Stocks to Invest In

Insider Monkey
·
18 Mar

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

PR Newswire
·
17 Mar

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research
·
17 Mar

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Business Wire
·
14 Mar

3 Industrials Stocks Walking a Fine Line

StockStory
·
13 Mar

CR Sanjiu Logs 18% Boost in 2024 Profit

MT Newswires Live
·
13 Mar

The Agfa-Gevaert Group in 2024: strong performance from growth engines offsets decline in traditional film markets - regulated information

GlobeNewswire
·
12 Mar

CR Double-Crane Pharmaceutical Gets Nod to Raise Specification of Sugammadex Sodium Injection

MT Newswires Live
·
12 Mar

Crane Is Maintained at Buy by DA Davidson

Dow Jones
·
11 Mar

D.A. Davidson Remains a Buy on Crane Company (CR)

TIPRANKS
·
11 Mar

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

PR Newswire
·
11 Mar

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
11 Mar

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GlobeNewswire
·
10 Mar

GoodRx Holdings, Inc. (GDRX): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock?

Insider Monkey
·
10 Mar

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Business Wire
·
10 Mar